With the forthcoming release of a Crispr-based genetic editing drug for neurological diseases, we’re about to enter a new age of medicine. The Nobel laureate sits down with WIRED’s Emily Mullin and talks about her outlook for this era of innovation in medicine, what other industries Crispr is poised to enhance, and the impact of this radical new approach on longevity and health.
